Nature of Regulatory T Cells in the Context of Allergic Disease

Allergy, Asthma & Clinical Immunology

Cevdet Ozdemir¹  Mübeccel Akdis²  Cezmi A Akdis² 

[1] Division of Pediatric Allergy and Immunology, Istanbul, Turkey

[2] Swiss Institute of Allergy and Asthma Research, Davos, Switzerland

关键词: allergen-specific immunotherapy;    regulatory T cells;    mucosal tolerance;    dendritic cells;   

Others  :  1083803
DOI  :  10.1186/1710-1492-4-3-106

【 授权许可】

   
2008 Canadian Society of Allergy and Clinical Immunology

【 参考文献 】

• [1]Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 119:780-91.
• [2]Romagnani S: Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004, 113:395-400.
• [3]Larché M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6:761-71.
• [4]Marcotte GV, Braun CM, Norman PS, et al.: Effects of peptide therapy on ex vivo T cell responses. J Allergy Clin Immunol 1998, 101:506-13.
• [5]Lai L, Casale TB, Stokes J: Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am 2005, 25:283-99.
• [6]Jutel M, Akdis M, Blaser K, Akdis CA: Mechanisms of allergen specific immunotherapy--T-cell tolerance and more. Allergy 2006, 61:796-807.
• [7]Calderon MA, Alves B, Jacobson M, et al.: Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, (1):CD001936.
• [8]Frew AJ: How does sublingual immunotherapy work? J Allergy Clin Immunol 2007, 120:533-6.
• [9]Wilson DR, Lima MT, Durham SR: Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60:4-12.
• [10]Kussebi F, Karamloo F, Akdis M, et al.: Advances in immunological treatment of allergy. Curr Med Chem 2003, 2:297-308.
• [11]Bahceciler NN, Ozdemir C, Barlan IB: Immunologic aspects of sublingual immunotherapy in the treatment of allergy and asthma. Curr Med Chem 2007, 14:265-9.
• [12]Bousquet J, Lockey R, Malling HJ, et al.: Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998, 81:401-5.
• [13]Durham SR, Walker SM, Varga EM, et al.: Long-term clinical efficacy of grass pollen immunotherapy. N Engl J Med 1999, 341:468-75.
• [14]Ozdemir C, Yazi D, Gocmen I, et al.: Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007, 18:508-15.
• [15]Larché M: Regulatory T cells in allergy and asthma. Chest 2007, 132:1007-14.
• [16]Bohle B, Kinaciyan T, Gerstmayr M, et al.: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergenspecific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007, 120:707-13.
• [17]Larché M: Immunoregulation by targeting T cells in the treatment of allergy and asthma. Curr Opin Immunol 2006, 18:745-50.
• [18]Hawrylowicz CM, O'Garra A: Potential role of IL-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005, 5:271-83.
• [19]Jutel M, Müller UR, Fricker M, et al.: Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996, 26:1112-8.
• [20]Plewako H, Wosinska K, Arvidsson M, et al.: Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006, 141:346-53.
• [21]Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B: Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy 1995, 25:704-12.
• [22]Plewako H, Arvidsson M, Oancea I, et al.: The effect of specific immunotherapy on the expression of costimulatory molecules in late phase reaction of the skin in allergic patients. Clin Exp Allergy 2004, 34:1862-7.
• [23]Varney VA, Hamid QA, Gaga M, et al.: Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993, 92:644-51.
• [24]Durham SR, Ying S, Varney VA, et al.: Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996, 97:1356-65.
• [25]Wilson DR, Irani AM, Walker SM, et al.: Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001, 31:1705-13.
• [26]Rak S, Heinrich C, Jacobsen L, et al.: A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001, 108:921-8.
• [27]Durham SR, Varney MA, Gaga M, et al.: Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy 1999, 29:1490-6.
• [28]Shim JY, Kim BS, Cho SH, et al.: Allergen-specific conventional immunotherapy decreases immunoglobulin E mediated basophil histamine releasability. Clin Exp Allergy 2003, 33:52-7.
• [29]Marogna M, Spadolini I, Massolo A, et al.: J Allergy Clin Immunol. 2005, 115:1184-8.
• [30]Vermaelen KY, Carro-Muino I, Lambrecht BN, Pauwels RA: Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 2001, 193:51-60.
• [31]Jonuleit H, Schmitt E, Schuler G, et al.: Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000, 192:1213-22.
• [32]De Heer HJ, Hammad H, Soullié T, et al.: Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J Exp Med 2004, 200:89-98.
• [33]Allam JP, Novak N, Fuchs C, et al.: Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J Allergy Clin Immunol 2003, 112:141-8.
• [34]Van Wilsem EJ, Van Hoogstraten IM, Brevé J, et al.: Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994, 83:128-32.
• [35]Chen Y, Kuchroo VK, Inobe J, et al.: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-40.
• [36]Akdis CA, Blesken T, Akdis M, et al.: Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998, 102:98-106.
• [37]Jutel M, Akdis M, Budak F, et al.: IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003, 33:1205-14.
• [38]Sakaguchi S, Sakaguchi N, Asano M, et al.: Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-64.
• [39]Akdis M: Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol 2006, 18:738-44.
• [40]Mantel PY, Kuipers H, Boyman O, et al.: GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007, 5(12):e329.
• [41]Flicker S, Valenta R: Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003, 132:13-24.
• [42]Wachholz PA, Durham SR: Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol 2004, 4:313-8.
• [43]Mothes N, Heinzkill M, Drachenberg KJ, et al.: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003, 33:1198-208.
• [44]Visco V, Dolecek V, Denepoux S, et al.: Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996, 157:956-62.
• [45]Flicker S, Steinberger P, Norderhaug L, et al.: Conversion of grass pollen allergen specific human IgE into a protective IgG1 antibody. Eur J Immunol 2002, 32:2156-62.
• [46]Chen W, Jin W, Hardegen N, et al.: Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-86.